+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Precision Diagnostics Market Size, Share & Trends Analysis Report By End-use, By Type, By Application (Oncology, Respiratory Diseases, CNS Disorders, Immunology, Skin Diseases, Genetic Diseases, and Others), By Regional Outlook and Forecast, 2024 - 2031

  • PDF Icon

    Report

  • 280 Pages
  • July 2024
  • Region: Global
  • Marqual IT Solutions Pvt. Ltd (KBV Research)
  • ID: 5988736
The Global Precision Diagnostics Market size is expected to reach $55.3 billion by 2031, rising at a market growth of 18% CAGR during the forecast period.

Precision diagnostics play a crucial role in early detection of cancer by identifying genetic predispositions and biomarkers associated with different cancer types. Early diagnosis allows for timely intervention, potentially improving patient outcomes through earlier initiation of treatment and monitoring of disease progression. The rising rates of cancer are increasing the demand for precision diagnostics in oncology. For instance, as per the New York State, each year, nearly 115,000 New Yorkers are diagnosed with cancer. Thus, the oncology segment acquired 23% revenue share in the market 2023.



The major strategies followed by the market participants is Partnership as the key developmental strategy to keep pace with the changing demands of end users. For instance, In February, 2024, F. Hoffmann-La Roche Ltd. and PathAI entered an exclusive agreement to develop AI-enabled digital pathology algorithms for companion diagnostics. This collaboration aims to accelerate innovations in personalized healthcare and enhance digital pathology integration for improved diagnostics and precision therapeutics. Additionally, In May, 2024, bioMérieux partnered with AnaBioTec to enhance Mycoplasma testing in biopharmaceutical and Cell & Gene Therapy industries in Europe. Their collaboration aims to streamline testing with BIOFIRE® Mycoplasma, offering rapid, automated PCR detection to improve manufacturing efficiency and regulatory compliance.

Cardinal Matrix - Market Competition Analysis

Based on the Analysis presented in the Cardinal matrix; F. Hoffmann-La Roche Ltd. is the forerunners in the Precision Diagnostics Market. Companies such as Thermo Fisher Scientific, Inc., Abbott Laboratories, and Danaher Corporation are some of the key innovators in Precision Diagnostics Market. In March, 2024, Thermo Fisher Scientific and Bayer AG have entered into a partnership to develop next-generation sequencing-based companion diagnostic assays for Bayer’s precision cancer therapies. This partnership aims to improve patient access through decentralized genomic testing, utilizing Thermo Fisher’s Ion Torrent Genexus Dx System with rapid turnaround times.



COVID-19 Impact Analysis

Economic uncertainties caused by the pandemic led to budget constraints in healthcare systems and reduced spending on non-essential healthcare services, including precision diagnostics. Clinical trials for new diagnostic technologies and products were delayed or halted due to restrictions on non-essential research activities and challenges in patient recruitment during the pandemic. Thus, the COVID-19 pandemic had a negative impact on the market.

Market Growth Factors

Precision diagnostics enable healthcare providers to tailor treatment strategies based on individual genetic profiles, biomarker patterns, and disease characteristics. This shift towards personalized medicine improves treatment efficacy, minimizes adverse effects, and optimizes healthcare resource allocation. Also, as the global population ages, the incidence of chronic diseases increases. Hence, the rising prevalence of chronic diseases worldwide is driving the growth of the market.

As healthcare infrastructure expands, more facilities are equipped with state-of-the-art diagnostic technologies. This increases the accessibility of precision diagnostics to a larger population, including those in rural and underserved areas.

Market Restraining Factors

Developing precision diagnostic technologies involves substantial R&D expenditures to innovate and refine technologies such as genomic sequencing, digital imaging, and molecular diagnostics. Prototyping and testing phases require specialized equipment and expertise, contributing to high upfront costs. Therefore, high initial investment and operational costs hinder the market's growth.

Driving and Restraining Factors

Drivers
  • Rising demand for non-invasive diagnostics
  • Expansion of healthcare infrastructure
  • Rising prevalence of chronic diseases worldwide
Restraints
  • High initial investment and operational costs
  • Limited reimbursement and uncertain payment models
Opportunities
  • Increasing government initiatives and funding
  • Rising patient-centric healthcare trends
Challenges
  • Insufficient clinical validation and evidence
  • Privacy concerns and ethical issues

End Use Outlook

By end-use, the market is categorized into hospitals, clinical laboratories, and others. In 2023, the clinical laboratories segment registered 46% revenue share in the market. Clinical laboratories possess the infrastructure, equipment, and expertise required to perform a wide range of diagnostic tests, including molecular testing, genetic analysis, biochemical assays, and imaging studies.

Type Outlook

Based on type, the market is divided into genetic tests, direct to consumer tests, esoteric tests, and others. In 2023 the DTC segment acquired 12% revenue share in the market 2023. DTC tests offer convenience by allowing consumers to order diagnostic tests online or through retail outlets without needing a healthcare provider's referral.



Application Outlook

On the basis of application, the market is segmented into oncology, respiratory diseases, skin diseases, CNS disorders, immunology, genetic diseases, and others. The skin diseases segment attained 8% revenue share in the market in 2023.

By Regional Analysis

Region-wise, the market is analyzed across North America, Europe, Asia Pacific, and LAMEA. In 2023, the Asia Pacific region generated 23% revenue share in the market. Rising incidences of chronic diseases such as diabetes, cardiovascular diseases, and cancer are prevalent in the Asia-Pacific region.

Market Competition and Attributes



The Precision Diagnostic Treatment market is highly competitive, driven by rapid technological advancements in AI, molecular diagnostics, and genomics. Key players focus on enhancing diagnostic accuracy and personalized medicine, optimizing treatments based on individual genetic profiles. Attributes such as high precision, early disease detection, and rapid treatment adjustments are paramount. The market sees significant investments in R&D, with collaborations between biotech firms, healthcare providers, and tech companies to innovate and improve patient outcomes in a fast-evolving landscape.

Recent Strategies Deployed in the Market

  • May-2024: bioMérieux partnered with AnaBioTec to enhance Mycoplasma testing in biopharmaceutical and Cell & Gene Therapy industries in Europe. Their collaboration aims to streamline testing with BIOFIRE® Mycoplasma, offering rapid, automated PCR detection to improve manufacturing efficiency and regulatory compliance.
  • May-2024: QIAGEN N.V announces the launch of the QIAseq Multimodal DNA/RNA Library Kit, facilitating efficient preparation of DNA and RNA libraries for multiomic studies and Comprehensive Genomic Profiling. This advancement enhances precision medicine by providing flexible and sensitive sequencing solutions from a single sample.
  • Apr-2024: Agilent Technologies and Transcenta Holding Limited have announced a collaboration to develop Claudin18.2 IHC 14G11 pharmDx, a companion diagnostic for Osemitamab's Phase III trial in gastric/gastroesophageal junction (GEJ) adenocarcinoma. This initiative is intended to optimize patient selection and enhance treatment outcomes, utilizing Agilent's proficiency in precision oncology diagnostics.
  • Mar-2024: Thermo Fisher Scientific and Bayer AG have entered a partnership to develop next-generation sequencing-based companion diagnostic assays for Bayer’s precision cancer therapies. This partnership aims to improve patient access through decentralized genomic testing, utilizing Thermo Fisher’s Ion Torrent Genexus Dx System with rapid turnaround times.
  • Feb-2024: Roche and PathAI have entered an exclusive agreement to develop AI-enabled digital pathology algorithms for companion diagnostics. This collaboration aims to accelerate innovations in personalized healthcare and enhance digital pathology integration for improved diagnostics and precision therapeutics.

List of Key Companies Profiled

  • Abbott Laboratories
  • F.Hoffmann-La Roche Ltd.
  • Siemens Healthineers AG (Siemens AG)
  • Thermo Fisher Scientific, Inc.
  • Danaher Corporation
  • Agilent Technologies, Inc.
  • BioMerieux S.A.
  • Becton, Dickinson and Company
  • Qiagen N.V
  • Hologic, Inc.

Market Report Segmentation

By End-use
  • Clinical Laboratories
  • Hospitals
  • Others
By Type
  • Genetic Tests
  • Esoteric Tests
  • Direct to Consumer Tests
  • Others
By Application
  • Oncology
  • Respiratory Diseases
  • CNS Disorders
  • Immunology
  • Skin Diseases
  • Genetic Diseases
  • Others
By Geography
  • North America
  • US
  • Canada
  • Mexico
  • Rest of North America
  • Europe
  • Germany
  • UK
  • France
  • Russia
  • Spain
  • Italy
  • Rest of Europe
  • Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Singapore
  • Malaysia
  • Rest of Asia Pacific
  • LAMEA
  • Brazil
  • Argentina
  • UAE
  • Saudi Arabia
  • South Africa
  • Nigeria
  • Rest of LAMEA

Table of Contents

Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 Global Precision Diagnostics Market, by End-use
1.4.2 Global Precision Diagnostics Market, by Type
1.4.3 Global Precision Diagnostics Market, by Application
1.4.4 Global Precision Diagnostics Market, by Geography
1.5 Methodology for the research
Chapter 2. Market at a Glance
2.1 Key Highlights
Chapter 3. Market Overview
3.1 Introduction
3.1.1 Overview
3.1.1.1 Market Composition and Scenario
3.2 Key Factors Impacting the Market
3.2.1 Market Drivers
3.2.2 Market Restraints
3.2.3 Market Opportunities
3.2.4 Market Challenges
Chapter 4. Competition Analysis - Global
4.1 Cardinal Matrix
4.2 Recent Industry Wide Strategic Developments
4.2.1 Partnerships, Collaborations and Agreements
4.2.2 Product Launches and Product Expansions
4.2.3 Acquisition and Mergers
4.3 Top Winning Strategies
4.3.1 Key Leading Strategies: Percentage Distribution (2020-2024)
4.3.2 Key Strategic Move: (Partnerships, Collaborations & Agreements: 2021, Jul - 2024, May) Leading Players
4.4 Porter Five Forces Analysis
Chapter 5. Global Precision Diagnostics Market by End-use
5.1 Global Clinical Laboratories Market by Region
5.2 Global Hospitals Market by Region
5.3 Global Others Market by Region
Chapter 6. Global Precision Diagnostics Market by Type
6.1 Global Genetic Tests Market by Region
6.2 Global Esoteric Tests Market by Region
6.3 Global Direct to Consumer Tests Market by Region
6.4 Global Others Market by Region
Chapter 7. Global Precision Diagnostics Market by Application
7.1 Global Oncology Market by Region
7.2 Global Respiratory Diseases Market by Region
7.3 Global CNS Disorders Market by Region
7.4 Global Immunology Market by Region
7.5 Global Skin Diseases Market by Region
7.6 Global Genetic Diseases Market by Region
7.7 Global Others Market by Region
Chapter 8. Global Precision Diagnostics Market by Region
8.1 North America Precision Diagnostics Market
8.1.1 North America Precision Diagnostics Market by End-use
8.1.1.1 North America Clinical Laboratories Market by Country
8.1.1.2 North America Hospitals Market by Country
8.1.1.3 North America Others Market by Country
8.1.2 North America Precision Diagnostics Market by Type
8.1.2.1 North America Genetic Tests Market by Country
8.1.2.2 North America Esoteric Tests Market by Country
8.1.2.3 North America Direct to Consumer Tests Market by Country
8.1.2.4 North America Others Market by Country
8.1.3 North America Precision Diagnostics Market by Application
8.1.3.1 North America Oncology Market by Country
8.1.3.2 North America Respiratory Diseases Market by Country
8.1.3.3 North America CNS Disorders Market by Country
8.1.3.4 North America Immunology Market by Country
8.1.3.5 North America Skin Diseases Market by Country
8.1.3.6 North America Genetic Diseases Market by Country
8.1.3.7 North America Others Market by Country
8.1.4 North America Precision Diagnostics Market by Country
8.1.4.1 US Precision Diagnostics Market
8.1.4.1.1 US Precision Diagnostics Market by End-use
8.1.4.1.2 US Precision Diagnostics Market by Type
8.1.4.1.3 US Precision Diagnostics Market by Application
8.1.4.2 Canada Precision Diagnostics Market
8.1.4.2.1 Canada Precision Diagnostics Market by End-use
8.1.4.2.2 Canada Precision Diagnostics Market by Type
8.1.4.2.3 Canada Precision Diagnostics Market by Application
8.1.4.3 Mexico Precision Diagnostics Market
8.1.4.3.1 Mexico Precision Diagnostics Market by End-use
8.1.4.3.2 Mexico Precision Diagnostics Market by Type
8.1.4.3.3 Mexico Precision Diagnostics Market by Application
8.1.4.4 Rest of North America Precision Diagnostics Market
8.1.4.4.1 Rest of North America Precision Diagnostics Market by End-use
8.1.4.4.2 Rest of North America Precision Diagnostics Market by Type
8.1.4.4.3 Rest of North America Precision Diagnostics Market by Application
8.2 Europe Precision Diagnostics Market
8.2.1 Europe Precision Diagnostics Market by End-use
8.2.1.1 Europe Clinical Laboratories Market by Country
8.2.1.2 Europe Hospitals Market by Country
8.2.1.3 Europe Others Market by Country
8.2.2 Europe Precision Diagnostics Market by Type
8.2.2.1 Europe Genetic Tests Market by Country
8.2.2.2 Europe Esoteric Tests Market by Country
8.2.2.3 Europe Direct to Consumer Tests Market by Country
8.2.2.4 Europe Others Market by Country
8.2.3 Europe Precision Diagnostics Market by Application
8.2.3.1 Europe Oncology Market by Country
8.2.3.2 Europe Respiratory Diseases Market by Country
8.2.3.3 Europe CNS Disorders Market by Country
8.2.3.4 Europe Immunology Market by Country
8.2.3.5 Europe Skin Diseases Market by Country
8.2.3.6 Europe Genetic Diseases Market by Country
8.2.3.7 Europe Others Market by Country
8.2.4 Europe Precision Diagnostics Market by Country
8.2.4.1 Germany Precision Diagnostics Market
8.2.4.1.1 Germany Precision Diagnostics Market by End-use
8.2.4.1.2 Germany Precision Diagnostics Market by Type
8.2.4.1.3 Germany Precision Diagnostics Market by Application
8.2.4.2 UK Precision Diagnostics Market
8.2.4.2.1 UK Precision Diagnostics Market by End-use
8.2.4.2.2 UK Precision Diagnostics Market by Type
8.2.4.2.3 UK Precision Diagnostics Market by Application
8.2.4.3 France Precision Diagnostics Market
8.2.4.3.1 France Precision Diagnostics Market by End-use
8.2.4.3.2 France Precision Diagnostics Market by Type
8.2.4.3.3 France Precision Diagnostics Market by Application
8.2.4.4 Russia Precision Diagnostics Market
8.2.4.4.1 Russia Precision Diagnostics Market by End-use
8.2.4.4.2 Russia Precision Diagnostics Market by Type
8.2.4.4.3 Russia Precision Diagnostics Market by Application
8.2.4.5 Spain Precision Diagnostics Market
8.2.4.5.1 Spain Precision Diagnostics Market by End-use
8.2.4.5.2 Spain Precision Diagnostics Market by Type
8.2.4.5.3 Spain Precision Diagnostics Market by Application
8.2.4.6 Italy Precision Diagnostics Market
8.2.4.6.1 Italy Precision Diagnostics Market by End-use
8.2.4.6.2 Italy Precision Diagnostics Market by Type
8.2.4.6.3 Italy Precision Diagnostics Market by Application
8.2.4.7 Rest of Europe Precision Diagnostics Market
8.2.4.7.1 Rest of Europe Precision Diagnostics Market by End-use
8.2.4.7.2 Rest of Europe Precision Diagnostics Market by Type
8.2.4.7.3 Rest of Europe Precision Diagnostics Market by Application
8.3 Asia Pacific Precision Diagnostics Market
8.3.1 Asia Pacific Precision Diagnostics Market by End-use
8.3.1.1 Asia Pacific Clinical Laboratories Market by Country
8.3.1.2 Asia Pacific Hospitals Market by Country
8.3.1.3 Asia Pacific Others Market by Country
8.3.2 Asia Pacific Precision Diagnostics Market by Type
8.3.2.1 Asia Pacific Genetic Tests Market by Country
8.3.2.2 Asia Pacific Esoteric Tests Market by Country
8.3.2.3 Asia Pacific Direct to Consumer Tests Market by Country
8.3.2.4 Asia Pacific Others Market by Country
8.3.3 Asia Pacific Precision Diagnostics Market by Application
8.3.3.1 Asia Pacific Oncology Market by Country
8.3.3.2 Asia Pacific Respiratory Diseases Market by Country
8.3.3.3 Asia Pacific CNS Disorders Market by Country
8.3.3.4 Asia Pacific Immunology Market by Country
8.3.3.5 Asia Pacific Skin Diseases Market by Country
8.3.3.6 Asia Pacific Genetic Diseases Market by Country
8.3.3.7 Asia Pacific Others Market by Country
8.3.4 Asia Pacific Precision Diagnostics Market by Country
8.3.4.1 China Precision Diagnostics Market
8.3.4.1.1 China Precision Diagnostics Market by End-use
8.3.4.1.2 China Precision Diagnostics Market by Type
8.3.4.1.3 China Precision Diagnostics Market by Application
8.3.4.2 Japan Precision Diagnostics Market
8.3.4.2.1 Japan Precision Diagnostics Market by End-use
8.3.4.2.2 Japan Precision Diagnostics Market by Type
8.3.4.2.3 Japan Precision Diagnostics Market by Application
8.3.4.3 India Precision Diagnostics Market
8.3.4.3.1 India Precision Diagnostics Market by End-use
8.3.4.3.2 India Precision Diagnostics Market by Type
8.3.4.3.3 India Precision Diagnostics Market by Application
8.3.4.4 South Korea Precision Diagnostics Market
8.3.4.4.1 South Korea Precision Diagnostics Market by End-use
8.3.4.4.2 South Korea Precision Diagnostics Market by Type
8.3.4.4.3 South Korea Precision Diagnostics Market by Application
8.3.4.5 Singapore Precision Diagnostics Market
8.3.4.5.1 Singapore Precision Diagnostics Market by End-use
8.3.4.5.2 Singapore Precision Diagnostics Market by Type
8.3.4.5.3 Singapore Precision Diagnostics Market by Application
8.3.4.6 Malaysia Precision Diagnostics Market
8.3.4.6.1 Malaysia Precision Diagnostics Market by End-use
8.3.4.6.2 Malaysia Precision Diagnostics Market by Type
8.3.4.6.3 Malaysia Precision Diagnostics Market by Application
8.3.4.7 Rest of Asia Pacific Precision Diagnostics Market
8.3.4.7.1 Rest of Asia Pacific Precision Diagnostics Market by End-use
8.3.4.7.2 Rest of Asia Pacific Precision Diagnostics Market by Type
8.3.4.7.3 Rest of Asia Pacific Precision Diagnostics Market by Application
8.4 LAMEA Precision Diagnostics Market
8.4.1 LAMEA Precision Diagnostics Market by End-use
8.4.1.1 LAMEA Clinical Laboratories Market by Country
8.4.1.2 LAMEA Hospitals Market by Country
8.4.1.3 LAMEA Others Market by Country
8.4.2 LAMEA Precision Diagnostics Market by Type
8.4.2.1 LAMEA Genetic Tests Market by Country
8.4.2.2 LAMEA Esoteric Tests Market by Country
8.4.2.3 LAMEA Direct to Consumer Tests Market by Country
8.4.2.4 LAMEA Others Market by Country
8.4.3 LAMEA Precision Diagnostics Market by Application
8.4.3.1 LAMEA Oncology Market by Country
8.4.3.2 LAMEA Respiratory Diseases Market by Country
8.4.3.3 LAMEA CNS Disorders Market by Country
8.4.3.4 LAMEA Immunology Market by Country
8.4.3.5 LAMEA Skin Diseases Market by Country
8.4.3.6 LAMEA Genetic Diseases Market by Country
8.4.3.7 LAMEA Others Market by Country
8.4.4 LAMEA Precision Diagnostics Market by Country
8.4.4.1 Brazil Precision Diagnostics Market
8.4.4.1.1 Brazil Precision Diagnostics Market by End-use
8.4.4.1.2 Brazil Precision Diagnostics Market by Type
8.4.4.1.3 Brazil Precision Diagnostics Market by Application
8.4.4.2 Argentina Precision Diagnostics Market
8.4.4.2.1 Argentina Precision Diagnostics Market by End-use
8.4.4.2.2 Argentina Precision Diagnostics Market by Type
8.4.4.2.3 Argentina Precision Diagnostics Market by Application
8.4.4.3 UAE Precision Diagnostics Market
8.4.4.3.1 UAE Precision Diagnostics Market by End-use
8.4.4.3.2 UAE Precision Diagnostics Market by Type
8.4.4.3.3 UAE Precision Diagnostics Market by Application
8.4.4.4 Saudi Arabia Precision Diagnostics Market
8.4.4.4.1 Saudi Arabia Precision Diagnostics Market by End-use
8.4.4.4.2 Saudi Arabia Precision Diagnostics Market by Type
8.4.4.4.3 Saudi Arabia Precision Diagnostics Market by Application
8.4.4.5 South Africa Precision Diagnostics Market
8.4.4.5.1 South Africa Precision Diagnostics Market by End-use
8.4.4.5.2 South Africa Precision Diagnostics Market by Type
8.4.4.5.3 South Africa Precision Diagnostics Market by Application
8.4.4.6 Nigeria Precision Diagnostics Market
8.4.4.6.1 Nigeria Precision Diagnostics Market by End-use
8.4.4.6.2 Nigeria Precision Diagnostics Market by Type
8.4.4.6.3 Nigeria Precision Diagnostics Market by Application
8.4.4.7 Rest of LAMEA Precision Diagnostics Market
8.4.4.7.1 Rest of LAMEA Precision Diagnostics Market by End-use
8.4.4.7.2 Rest of LAMEA Precision Diagnostics Market by Type
8.4.4.7.3 Rest of LAMEA Precision Diagnostics Market by Application
Chapter 9. Company Profiles
9.1 Abbott Laboratories
9.1.1 Company Overview
9.1.2 Financial Analysis
9.1.3 Segmental and Regional Analysis
9.1.4 Research & Development Expense
9.1.5 Recent strategies and developments:
9.1.5.1 Acquisition and Mergers:
9.1.6 SWOT Analysis
9.2 F. Hoffmann-La Roche Ltd.
9.2.1 Company Overview
9.2.2 Financial Analysis
9.2.3 Segmental and Regional Analysis
9.2.4 Research & Development Expense
9.2.5 Recent strategies and developments:
9.2.5.1 Partnerships, Collaborations, and Agreements:
9.2.5.2 Product Launches and Product Expansions:
9.2.6 SWOT Analysis
9.3 Siemens Healthineers AG (Siemens AG)
9.3.1 Company Overview
9.3.2 Financial Analysis
9.3.3 Segmental and Regional Analysis
9.3.4 Research & Development Expense
9.3.5 Recent strategies and developments:
9.3.5.1 Partnerships, Collaborations, and Agreements:
9.3.5.2 Product Launches and Product Expansions:
9.3.5.3 Acquisition and Mergers:
9.3.6 SWOT Analysis
9.4 Thermo Fisher Scientific, Inc.
9.4.1 Company Overview
9.4.2 Financial Analysis
9.4.3 Segmental and Regional Analysis
9.4.4 Research & Development Expenses
9.4.5 Recent strategies and developments:
9.4.5.1 Partnerships, Collaborations, and Agreements:
9.4.6 SWOT Analysis
9.5 Danaher Corporation
9.5.1 Company Overview
9.5.2 Financial Analysis
9.5.3 Segmental and Regional Analysis
9.5.4 Research & Development Expense
9.5.5 Recent strategies and developments:
9.5.6 SWOT Analysis
9.6 Agilent Technologies, Inc.
9.6.1 Company Overview
9.6.2 Financial Analysis
9.6.3 Segmental and Regional Analysis
9.6.4 Research & Development Expense
9.6.5 Recent strategies and developments:
9.6.5.1 Partnerships, Collaborations, and Agreements:
9.6.5.2 Product Launches and Product Expansions:
9.6.6 SWOT Analysis
9.7 BioMerieux S.A.
9.7.1 Company Overview
9.7.2 Financial Analysis
9.7.3 Segmental and Regional Analysis
9.7.4 Research & Development Expenses
9.7.5 Recent strategies and developments:
9.7.5.1 Partnerships, Collaborations, and Agreements:
9.7.5.2 Acquisition and Mergers:
9.7.6 SWOT Analysis
9.8 Becton, Dickinson, and Company
9.8.1 Company Overview
9.8.2 Financial Analysis
9.8.3 Segmental and Regional Analysis
9.8.4 Research & Development Expense
9.8.5 SWOT Analysis
9.9 Qiagen N.V.
9.9.1 Company Overview
9.9.2 Financial Analysis
9.9.3 Regional Analysis
9.9.4 Research & Development Expenses
9.9.5 Recent strategies and developments:
9.9.5.1 Partnerships, Collaborations, and Agreements:
9.9.5.2 Product Launches and Product Expansions:
9.9.6 SWOT Analysis
9.10. Hologic, Inc.
9.10.1 Company Overview
9.10.2 Financial Analysis
9.10.3 Segmental and Regional Analysis
9.10.4 Research & Development Expenses
9.10.5 SWOT Analysis
Chapter 10. Winning Imperatives of Precision Diagnostics Market

Companies Mentioned

  • Abbott Laboratories
  • F. Hoffmann-La Roche Ltd.
  • Siemens Healthineers AG (Siemens AG)
  • Thermo Fisher Scientific, Inc.
  • Danaher Corporation
  • Agilent Technologies, Inc.
  • BioMerieux S.A.
  • Becton, Dickinson and Company
  • Qiagen N.V
  • Hologic, Inc.

Methodology

Loading
LOADING...